Diamyd Medical: Funding, Investors & Team (Sep 2026)
Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for Type 1 Diabetes. The therapeutic diabetes vaccine Diamyd , an antigen-specific immunotherapy for the preservation of endogenous insulin production, is being evaluated in the ongoing Phase III trial DIAGNODE-3. The company is establishing a vaccine manufacturing facility in Umeå for the manufacture of recombinant GAD65, the active ingredient in the diabetes vaccine. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB. The Diamyd Medical share is traded on Nasdaq First North Growth Market, ticker DMYD B.
Diamyd Medical has raised $14.9M across 3 funding rounds on record, the most recent an undisclosed round of $4.7M announced in Oct 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Diamyd Medical Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Diamyd Medical Funding Rounds
Diamyd Medical raised $5.0M in an undisclosed round announced in Apr 2023.
1 years later, an undisclosed round of $5.2M was announced in Apr 2024.
6 months later, an undisclosed round of $4.7M was announced in Oct 2024.
Diamyd Medical Founders and Leadership Team
Contact details for the Diamyd Medical team: 1 of 1 has an email address on file.
Start 14-day free trial →Diamyd Medical Funding Compared to Other Biotechnology Startups
Diamyd Medical's latest round of $4.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Diamyd Medical in Biotechnology and Stockholm
Companies Similar to Diamyd Medical
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Diamyd Medical Funding FAQs
What does Diamyd Medical do?
Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for Type 1 Diabetes. The therapeutic diabetes vaccine Diamyd , an antigen-specific immunotherapy for the preservation of endogenous insulin production, is being evaluated in the ongoing Phase III trial DIAGNODE-3. The company is establishing a vaccine manufacturing facility in Umeå for the manufacture of recombinant GAD65, the active ingredient in the diabetes vaccine. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB. The Diamyd Medical share is traded on Nasdaq First North Growth Market, ticker DMYD B.
How much funding has Diamyd Medical raised?
Diamyd Medical has raised $14.9M across 3 rounds on record. The most recent is an undisclosed round of $4.7M announced in Oct 2024.
When did Diamyd Medical last raise funding?
Diamyd Medical's most recent funding round on record is an undisclosed round of $4.7M, announced in Oct 2024.
Who founded Diamyd Medical?
FundedIQ lists Ulf Hannelius (Founder) at Diamyd Medical.
Where is Diamyd Medical headquartered?
Diamyd Medical is based in Stockholm, Stockholms Lan, Sweden.
How many employees does Diamyd Medical have?
Diamyd Medical is in the 1-10 employee band.
How does Diamyd Medical's funding compare to other Biotechnology startups?
Diamyd Medical's latest round of $4.7M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Diamyd Medical Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Diamyd Medical is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.